OrthoPediatrics (KIDS)
Nasdaq Market Closed
OrthoPediatrics Corp. is a medical technology company focused exclusively on orthopedic conditions affecting children. Unlike broad-based orthopedic device makers that primarily design products for adult anatomy, OrthoPediatrics develops implants, instruments, and related solutions specifically sized and engineered for pediatric patients and the surgeons who treat them.
The company’s portfolio addresses several areas of pediatric orthopedics, including trauma, deformity correction, scoliosis, sports medicine, and specialized limb and extremity procedures. Its product families include systems such as PediLoc, PediPlates, cannulated screws, PediFlex, PediNail, tibia fixation products, and pediatric ACL reconstruction solutions. These devices are intended to help surgeons manage fractures, growth-related deformities, congenital conditions, and injuries in children and adolescents.
OrthoPediatrics operates in a niche of the medical device market where clinical needs can differ significantly from adult care. Children’s bones are still growing, and orthopedic implants must account for smaller anatomy, growth plates, and long-term developmental considerations. The company supports this specialty focus with dedicated instrument sets, surgeon education, and a sales organization oriented toward pediatric hospitals and orthopedic specialists.
The company reports its activities through a single operating segment built around the design, development, and commercialization of pediatric orthopedic products. Its revenue is primarily tied to the use and sale of its implants and related surgical systems. For investors, KIDS offers exposure to a specialized healthcare market where product differentiation depends on clinical expertise, surgeon adoption, hospital relationships, regulatory execution, and the continuing expansion of treatment options for children with orthopedic disorders.
Last updated
- Market Cap
- 434.59M
- P/E
- —
- P/FCF
- —
- P/S
- 1.79
- Enterprise Value
- 522.72M
- Sector
- Health Care
- Industry
- Surgical and Medical Instruments and Apparatus
- Address
- 2850 FRONTIER DRIVE, WARSAW, IN, 46582
OrthoPediatrics Corp. Announces Distribution Agreement with MY01 Inc.
OrthoPediatrics Corp. Continued Leading Sponsorship at 2025 POSNA Annual Meeting
OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2024 and Issues 2025 Financial Guidance
OrthoPediatrics (KIDS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
CVRx (CVRX) Stock Jumps 33.9%: Will It Continue to Soar?
OrthoPediatrics Corp. to Participate in the Truist Securities MedTech Conference
OrthoPediatrics Corp. Continued Leading Sponsorship at 2024 EPOSNA Annual Meeting
OrthoPediatrics (KIDS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
OrthoPediatrics (KIDS) Reports Q1 Loss, Tops Revenue Estimates
OrthoPediatrics Corp. to Report First Quarter 2024 Financial Results on May 7, 2024
OrthoPediatrics Corp. to Highlight its Pediatric Scoliosis Solutions at 8th Annual International Children’s Spine Symposium (ICSS)
OrthoPediatrics Corp. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
OrthoPediatrics (KIDS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
OrthoPediatrics (KIDS) Reports Q4 Loss, Tops Revenue Estimates
OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results
OrthoPediatrics Corp. Launches New RESPONSE Rib and Pelvic Fixation System for EOS Scoliosis
OrthoPediatrics Corp. Named One of the 2024 Best Places to Work in Indiana
ReWalk Robotics (LFWD) Reports Q4 Loss, Misses Revenue Estimates
OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
OrthoPediatrics (KIDS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 434.59M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 522.72M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 1.28
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 1.79
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -113.61
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 2.15
- EPS
- -1.54
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -12.63M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -11.71%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -7.9%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.3
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 5.17
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 2.33
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.26
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 173.85K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 16.92
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 59.36M | 61.61M | 61.25M | 61.08M | 52.41M |
| Gross profit | 43.39M | 45.11M | 45.27M | 44.02M | 38.26M |
| Operating income | -8.34M | -8.17M | -9.43M | -10.66M | -10.98M |
| EBITDA | -2.61M | 96K | 433K | -2.52M | -5.89M |
| Net income | -10.69M | -10.1M | -11.77M | -7.11M | -10.66M |
| Basic EPS | -0.45 | -0.43 | -0.5 | -0.3 | -0.46 |
| Diluted EPS | -0.45 | -0.43 | -0.5 | -0.3 | -0.46 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 502.19M | 508.63M | 493.49M | 503.61M | 470.25M |
| Total liabilities | 163.48M | 162.03M | 144.18M | 148.09M | 123.1M |
| Total equity | 338.71M | 346.6M | 349.31M | 355.51M | 347.15M |
| Cash & equivalents | 12.19M | 19.56M | 16.83M | 44.55M | 33.44M |
| Current assets | 243.81M | 254.36M | 243.79M | 255.65M | 230.07M |
| Current liabilities | 47.18M | 46.2M | 33.23M | 38.67M | 37.51M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -3.29M | 10.35M | -581K | -10.46M | -4.16M |
| Investing cash flow | -3.79M | -7.26M | -26.84M | -3.55M | -5.99M |
| Financing cash flow | -614K | -417K | -282K | 24.8M | -126K |
| Change in cash | -7.38M | 2.74M | -27.72M | 11.18M | -10.35M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — ORTHOPEDIATRICS CORP | View Filing | |
| form 4 | Form 4 — Gerritzen Daniel J | View Filing | |
| edgar index | 10-Q — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | DEF 14A — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | DEFA14A — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | ARS — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 8-K — ORTHOPEDIATRICS CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 4 — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 4 — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 4 — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 4 — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 144 — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 144 — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 144 — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 144 — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 144 — ORTHOPEDIATRICS CORP | View Filing | |
| form 4 | Form 4 — Gerritzen Daniel J | View Filing | |
| form 4 | Form 4 — Odle Gregory A | View Filing | |
| form 4 | Form 4 — Bailey David R | View Filing | |
| form 4 | Form 4 — Hite Fred | View Filing | |
| form 4 | Form 4 — Hauser Joseph W | View Filing | |
| form 4 | Form 4 — Gerritzen Daniel J | View Filing | |
| form 4 | Form 4 — Odle Gregory A | View Filing | |
| form 4 | Form 4 — Hite Fred | View Filing | |
| form 4 | Form 4 — Hauser Joseph W | View Filing | |
| edgar index | 10-K — ORTHOPEDIATRICS CORP | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 8-K — ORTHOPEDIATRICS CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 8-K — ORTHOPEDIATRICS CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — ORTHOPEDIATRICS CORP | View Filing | |
| form 4 | Form 4 — Bailey David R | View Filing | |
| edgar index | SCHEDULE 13G/A — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 3 — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 4 — ORTHOPEDIATRICS CORP | View Filing | |
| form 3 | Form 3 — Fischer Kelly Laine | View Filing | |
| form 4 | Form 4 — Fischer Kelly Laine | View Filing | |
| edgar index | SCHEDULE 13G — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 10-Q — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 8-K — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 8-K — ORTHOPEDIATRICS CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — ORTHOPEDIATRICS CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — ORTHOPEDIATRICS CORP | View Filing | |
| form 4 | Form 4 — Hite Fred | View Filing | |
| edgar index | 8-K — ORTHOPEDIATRICS CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-Q — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 8-K — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 8-K — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 8-K — ORTHOPEDIATRICS CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | UPLOAD — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | CORRESP — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | UPLOAD — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | CORRESP — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 4 — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 4 — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 4 — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 4 — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 4 — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 4 — ORTHOPEDIATRICS CORP | View Filing | |
| edgar index | 4 — ORTHOPEDIATRICS CORP | View Filing |